Anavex Life Sciences Corp. (AVXL)
NASDAQ: AVXL · Real-Time Price · USD
4.790
+0.140 (3.01%)
At close: Mar 9, 2026, 4:00 PM EDT
4.800
+0.010 (0.21%)
After-hours: Mar 9, 2026, 7:48 PM EDT
Anavex Life Sciences Cash Flow Statement
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
| TTM
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
| Net Income | -39.95 | -46.38 | -43 | -47.51 | -47.98 | -37.91 | |
| Stock-Based Compensation | 10.6 | 11.55 | 9.44 | 16.37 | 18.38 | 8.23 | |
| Other Operating Activities | - | - | - | 0.85 | - | - | |
| Change in Accounts Payable | -1.93 | -5.38 | 5.31 | 0.5 | -0.91 | 0.75 | |
| Change in Unearned Revenue | -0.02 | -0.04 | -0.08 | 0.47 | - | 0.44 | |
| Change in Other Net Operating Assets | -2.78 | 1.2 | -2.48 | 1.54 | 6.28 | -1.9 | |
| Operating Cash Flow | -34.08 | -39.04 | -30.81 | -27.79 | -24.24 | -30.38 | |
| Issuance of Common Stock | 47.76 | 12.14 | 11.98 | 29.65 | 22 | 158.79 | |
| Repurchase of Common Stock | -2.71 | -2.71 | - | - | - | - | |
| Other Financing Activities | - | - | - | - | -0.71 | -5.55 | |
| Financing Cash Flow | 45.05 | 9.43 | 11.98 | 29.65 | 21.29 | 153.24 | |
| Net Cash Flow | 10.97 | -29.61 | -18.84 | 1.87 | -2.95 | 122.86 | |
| Cash Income Tax Paid | 0.12 | 0.13 | 0.3 | 0.14 | 0.33 | 0.14 | |
| Levered Free Cash Flow | -21.83 | -24.39 | -19.43 | -14.28 | -6.03 | -15.9 | |
| Unlevered Free Cash Flow | -21.83 | -24.39 | -19.43 | -14.28 | -6.03 | -15.9 | |
| Change in Working Capital | -4.73 | -4.22 | 2.75 | 2.51 | 5.36 | -0.71 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.